Organisation paid for research Program year 2024 Source: CMS Open Payments

Washington University School

Neither a doctor nor a teaching hospital

Research payments

$1,946,148

555 payments

Through program year 2024, Washington University School is reported as receiving $1,946,148 in research payments, across 555 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$608,770	36
2023	Research	$907,111	378
2022	Research	$273,657	113
2021	Research	$153,261	22
2020	Research	$3,350	6

Breakdown

Who paid Research payments · program years 2020–2024

Moderna TX, Inc. $1,451,824 364 payments
GlaxoSmithKline, LLC. $291,321 165 payments
Pfizer Inc. $123,620 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $30,500 1 payment
Takeda Pharmaceuticals U.S.A., Inc. $18,711 20 payments
ViiV Healthcare Company $11,979 1 payment
Regeneron Pharmaceuticals, Inc. $10,930 1 payment
Albireo Pharma, Inc. $7,264 2 payments

Studies the money was for Research payments · program years 2020–2024

Phase 2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 and Comparator Seasonal Influenza Vaccines in Healthy Adults $569,096 306 payments
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $225,472 18 payments
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma $178,970 15 payments
Master Protocol to Assess the Safety and Antitumor Activity of Genetic $158,529 91 payments
Research Agreement Administrative Database Analyses $123,620 1 payment
A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma. $114,272 2 payments
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of N $74,534 40 payments
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors $41,739 6 payments
A Phase 1B/2A Pilot Study to Evaluate the Safety and Tolerability of A $37,774 17 payments
Phase II III BI 907828 + BI 754091 in 1st L DD Lip $30,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.